Correction to Gilead Says Trodelvy Trial Didn't Meet Primary Endpoint Article
January 22 2024 - 9:32AM
Dow Jones News
Gilead agreed in 2020 to buy Trodelvy-maker Immunomedics for $21
billion. "Gilead Says Trodelvy Lung Cancer Trial Didn't Meet
Primary Endpoint" at 8:47 a.m. ET incorrectly said Gilead agreed in
2022 to buy Immunomedics.
(END) Dow Jones Newswires
January 22, 2024 09:17 ET (14:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024
